These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 18260941)

  • 1. [Hypotensive activity and cerebroprotective properties of carvedilol in patients with arterial hypertension associated with type 2 diabetes mellitus].
    Mordovin VF; Belokopytova NV; Fal'kovskaia AIu; Efimova IIu
    Kardiologiia; 2007; 47(10):31-6. PubMed ID: 18260941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug therapy of diastolic cardiac insufficiency in patients with type 2 diabetes and concomitant essential arterial hypertension].
    Iarkova NA; Borovkov NN
    Klin Med (Mosk); 2009; 87(10):25-9. PubMed ID: 20017346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Heart rate variability dynamics during treatment of arterial hypertension].
    Riabykina GV; Chazova IE; Mychka VB; Shutova LI; Shishova TV; Liutikova LN; Kozhemiakina ESh; Shchedrina EV; Sobolev AV
    Kardiologiia; 2008; 48(7):18-24. PubMed ID: 18789021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive effect of carvedilol: a preliminary dose-response study.
    Casadei B; Conway J; Coats AJ; Bird R
    Clin Investig; 1992; 70 Suppl 1():S37-8. PubMed ID: 1350482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled-release carvedilol in the treatment of essential hypertension.
    Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
    Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
    Ogihara T; Ikeda M; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S108-12. PubMed ID: 2454355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of carvedilol as third-line add-on therapy on blood pressure and glucose metabolism in type 2 diabetic patients with chronic renal disease stage 3 and above.
    Yasuda G; Yatsu K; Yamamoto Y; Hirawa N
    Kidney Blood Press Res; 2012; 36(1):131-8. PubMed ID: 23095799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.
    Galzerano D; Tammaro P; del Viscovo L; Lama D; Galzerano A; Breglio R; Tuccillo B; Paolisso G; Capogrosso P
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1563-9. PubMed ID: 16364826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
    Lund-Johansen P; Omvik P; Nordrehaug JE; White W
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S27-34. PubMed ID: 1378146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of combination antihypertensive therapy on circadian blood pressure and metabolic parameters in patients with type 2 diabetes mellitus].
    Statsenko ME; Derevianchenko MV; Pastukhova OR
    Kardiologiia; 2014; 54(11):20-4. PubMed ID: 25902654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [First results of open randomized clinical study of Acridilol in combination therapy of patients with arterial hypertension and obesity or type 2 diabetes (Mellitus-Open Multicenter Clinical Study ACCORD)].
    Shal'nova SA; Martsevich SIu; Deev AD; Lukina IuV; Oganov RG
    Kardiologiia; 2008; 48(8):28-33. PubMed ID: 18789007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics.
    Ehmer B; van der Does R; Rudorf J
    Drugs; 1988; 36 Suppl 6():136-40. PubMed ID: 2908300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of brerlipril in patients with non-insulin dependent diabetes mellitus and mild or moderate arterial hypertension as indicated by 24-h blood pressure monitoring].
    Ametov AS; Gubina EV; Nikolaev OG
    Ter Arkh; 1999; 71(8):17-20. PubMed ID: 10515028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Provision of complex cardioprotection with the help of carvedilol in 1-2 degree arterial hypertension combined with metabolic syndrome].
    Oleĭnikov VE; Matrosova IB; Eliseeva IV; Tomashevskaia IuA; Gusakovskaia LI
    Kardiologiia; 2009; 49(11):27-32. PubMed ID: 20001979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does carvedilol impair insulin sensitivity in heart failure patients without diabetes?
    Ferrua S; Bobbio M; Catalano E; Grassi G; Massobrio N; Pinach S; Rossi C; Veglio M; Trevi GP
    J Card Fail; 2005 Oct; 11(8):590-4. PubMed ID: 16230261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach.
    Stienen U; Meyer-Sabellek W
    Clin Investig; 1992; 70 Suppl 1():S65-72. PubMed ID: 1350487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative eficacy of antihypertensive therapy in patients with arterial hypertension and various sensitivity to salt].
    Babkin AP; Gladkikh VV; Pershukov IV; Gulaia GI
    Kardiologiia; 2010; 50(10):35-8. PubMed ID: 21118177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the antihypertensive properties of carvedilol, a compound with beta-blocking and vasodilating effects.
    Tanaka M; Masumura H; Tanaka S; Akashi A
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S52-7. PubMed ID: 2454368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol for systemic hypertension.
    Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S113-8. PubMed ID: 2454356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Arterial hypertension and type 2 diabetes mellitus: clinical evaluation of hemodynamic characteristics, possibility of correction].
    Tatarchenko IP; Pozdniakova NV; Mordovina AG; Sekerko SA; Morozova OI
    Klin Med (Mosk); 2009; 87(10):20-4. PubMed ID: 20017345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.